PMID- 33002608
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220502
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
VI  - 80
DP  - 2022 May
TI  - Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in 
      developing small-molecule inhibitors from natural compounds.
PG  - 379-390
LID - S1044-579X(20)30202-9 [pii]
LID - 10.1016/j.semcancer.2020.09.011 [doi]
AB  - Rapid progress in molecular cancer biology coupled with the discovery of novel 
      oncology drugs has opened new horizons for cancer target discovery. As one of the 
      crucial signaling pathways related to tumorigenesis, hypoxia-inducible factor-1 
      (HIF-1) coordinates the activity of many transcription factors and their 
      downstream molecules that impact tumor growth and metastasis. Accumulating 
      evidence suggests that the transcriptional responses to acute hypoxia are mainly 
      attributable to HIF-1alpha. Moreover, the overexpression of HIF-1alpha in several solid 
      cancers has been found to be strongly associated with poor prognosis. Thus, 
      pharmacological targeting of the HIF-1 signaling pathways has been considered as 
      a new strategy for cancer therapy in the recent years. Although over the past 
      decade, tremendous efforts have been made in preclinical studies to develop new 
      HIF-1 inhibitors from natural products (reservoirs of novel therapeutic agents), 
      to date, these efforts have not been successfully translated into clinically 
      available treatments. In this review, we provide new insights into the 
      bio-pharmacological considerations for selecting natural compounds as potential 
      HIF-1 inhibitors to accelerate anti-cancer drug development. In addition, we 
      highlighted the importance of assessing the dependency of cancer on HIF1A to 
      shortlist cancer types as suitable disease models. This may subsequently lead to 
      new paradigms for discovering more HIF-1 inhibitors derived from natural products 
      and facilitate the development of potent therapeutic agents targeting specific 
      cancer types.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Ma, Zhaowu
AU  - Ma Z
AD  - School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 
      Hubei 434023, China; The First School of Clinical Medicine, Health Science 
      Center, Yangtze University, Jingzhou, Hubei 434023k, China.
FAU - Xiang, Xiaoqiang
AU  - Xiang X
AD  - School of Pharmacy, Fudan University, Shanghai 201203, China.
FAU - Li, Shiya
AU  - Li S
AD  - Dyson School of Design Engineering, Imperial College London, London SW7 2AZ, 
      United Kingdom.
FAU - Xie, Peng
AU  - Xie P
AD  - School of Pharmacy, Fudan University, Shanghai 201203, China; China State 
      Institute of Pharmaceutical Industry, Shanghai 201203, China.
FAU - Gong, Quan
AU  - Gong Q
AD  - School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 
      Hubei 434023, China; The First School of Clinical Medicine, Health Science 
      Center, Yangtze University, Jingzhou, Hubei 434023k, China. Electronic address: 
      gongquan1998@163.com.
FAU - Goh, Boon-Cher
AU  - Goh BC
AD  - Department of Pharmacology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore 117600, Singapore; Department of Haematology-Oncology, 
      National University Cancer Institute, Singapore 119228, Singapore; Cancer Science 
      Institute of Singapore, National University of Singapore, Singapore 117599, 
      Singapore. Electronic address: phcgbc@nus.edu.sg.
FAU - Wang, Lingzhi
AU  - Wang L
AD  - Department of Pharmacology, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore 117600, Singapore; Cancer Science Institute of Singapore, 
      National University of Singapore, Singapore 117599, Singapore. Electronic 
      address: csiwl@nus.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200928
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Hypoxia-Inducible Factor 1)
SB  - IM
MH  - *Antineoplastic Agents/pharmacology/therapeutic use
MH  - *Biological Products/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoxia
MH  - Hypoxia-Inducible Factor 1/therapeutic use
MH  - *Neoplasms/pathology
OTO - NOTNLM
OT  - Cancer treatment
OT  - Hypoxia-inducible factor-1
OT  - Natural compounds
OT  - Small-molecule inhibitors
EDAT- 2020/10/02 06:00
MHDA- 2022/05/03 06:00
CRDT- 2020/10/01 20:11
PHST- 2020/02/03 00:00 [received]
PHST- 2020/09/06 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2020/10/01 20:11 [entrez]
AID - S1044-579X(20)30202-9 [pii]
AID - 10.1016/j.semcancer.2020.09.011 [doi]
PST - ppublish
SO  - Semin Cancer Biol. 2022 May;80:379-390. doi: 10.1016/j.semcancer.2020.09.011. 
      Epub 2020 Sep 28.